Mayne Pharma receives purported notice to terminate SID
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA RECEIVES PURPORTED NOTICE TO
TERMINATE SCHEME IMPLEMENTATION DEED FROM COSETTE
4 June 2025, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma) refers
to its announcements earlier today and on 21 May 2025 regarding correspondence from Cosette
Pharmaceuticals, Inc. (Cosette) dated 17 May 2025 under which Cosette asserted that a Mayne
Material Adverse Change had occurred and that the obligations under clauses 3.5(c) and 3.7(a)(ii)
of the scheme implementation deed dated 20 February 2025 (SID) had been triggered, in
particular the obligations on the parties to promptly consult with each other in good faith for 10
business days.
Following the release of Mayne Pharma’s announcement earlier today and the commencement
of trading, Mayne Pharma received a notice purporting to terminate the SID from Cosette for the
purposes of clause 3.7(b) and clause 15.1(a)(ii) of the SID (Cosette Termination Notice).
Additionally, within the Cosette Termination Notice, Cosette has indicated that if the Cosette
Termination Notice is held to be ineffective, Cosette gives notice of a purported breach by Mayne
Pharma of the Mayne Representation and Warranty (as defined in the SID), contained in
paragraph 15 of Schedule 2 to the SID (Cosette Additional Notice). In the Cosette Additional
Notice, Cosette has indicated an intention to terminate the SID if the circumstances giving rise to
the alleged breach continue to exist for five Business Days from today. The allegation of the
breach of warranty in the Cosette Additional Notice was not contained in the correspondence
from Cosette dated 17 May 2025.
Mayne Pharma has, together with its advisors, considered the Cosette Termination Notice and the
Cosette Additional Notice. Mayne Pharma intends to reject the Cosette Termination Notice as
invalid and reiterates its position that no Mayne Material Adverse Change (as defined in the SID)
has been triggered such that there is no lawful basis for Cosette to terminate the SID.
Mayne Pharma is considering the matters raised in the Cosette Additional Notice and will update
the market as soon as possible.
Mayne Pharma reserves all of its rights in connection with any failure by Cosette to perform its
obligations under the SID. Mayne Pharma intends to enforce its rights under the SID, including to
approach the Court to challenge the validity of the Cosette Termination Notice, and if appropriate,
any purported termination associated with the Cosette Additional Notice.
Mayne Pharma remains committed to the successful completion of the scheme in the interests of
all shareholders and maintains its position that all information relevant to the financial position
of Mayne Pharma has been disclosed to market, including most recently in the earnings
announcement released on 22 April 2025.
Mayne Pharma intends to apply to Court to approve supplementary disclosure to Mayne Pharma
Shareholders. Further updates on this will be provided to market in due course and Mayne
Pharma Shareholders do not need to take any action at this time in relation to the Cosette
Termination Notice or the Cosette Additional Notice.
ASX Announcement
If shareholders have any questions in relation to the Scheme Booklet or the Scheme, they should
contact the Mayne Pharma Shareholder Information Line on 1300 158 729 (within Australia) and
+61 2 9066 4058 (outside Australia), Monday to Friday between 9.00am and 5.00pm (AEST)
(excluding public holidays).
- ENDS Authorised for release to the ASX by the Board of Directors
For further information contact:
Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne
Pharma is a leader in dermatology and women’s health in the United States and also provides
contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40year track record of innovation and success in developing new oral drug delivery systems. These
technologies have been successfully commercialised in numerous products that continue to be
marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.
Page 2
Share your feedback
Discover